PT2805945T - Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors - Google Patents

Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Info

Publication number
PT2805945T
PT2805945T PT14176452T PT14176452T PT2805945T PT 2805945 T PT2805945 T PT 2805945T PT 14176452 T PT14176452 T PT 14176452T PT 14176452 T PT14176452 T PT 14176452T PT 2805945 T PT2805945 T PT 2805945T
Authority
PT
Portugal
Prior art keywords
parp
adp
ribose
polymerase
inhibitors
Prior art date
Application number
PT14176452T
Other languages
Portuguese (pt)
Inventor
Maria Ontoria Ontoria Jesus
Scarpeli Rita
Schultz-Fademrecht Carsten
Jones Philip
Original Assignee
Msd Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2805945(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Italia Srl filed Critical Msd Italia Srl
Publication of PT2805945T publication Critical patent/PT2805945T/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory discuses, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo and/or radiosensitizers for cancer treatment.
PT14176452T 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors PT2805945T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US92131007P 2007-04-02 2007-04-02

Publications (1)

Publication Number Publication Date
PT2805945T true PT2805945T (en) 2019-06-06

Family

ID=37809722

Family Applications (3)

Application Number Title Priority Date Filing Date
PT08702101T PT2109608E (en) 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
PT14176452T PT2805945T (en) 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
PT111573697T PT2336120E (en) 2007-01-10 2008-01-08 Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT08702101T PT2109608E (en) 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111573697T PT2336120E (en) 2007-01-10 2008-01-08 Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Country Status (21)

Country Link
CN (1) CN101578279B (en)
AT (1) ATE502933T1 (en)
CR (1) CR10910A (en)
DE (1) DE602008005711D1 (en)
DK (2) DK2336120T3 (en)
ES (3) ES2509115T3 (en)
GB (1) GB0700432D0 (en)
HN (1) HN2009001260A (en)
HU (1) HUE044513T2 (en)
LT (1) LT2805945T (en)
LU (1) LUC00072I2 (en)
ME (1) ME03481B (en)
MY (1) MY147789A (en)
NI (1) NI200900135A (en)
NZ (1) NZ578256A (en)
PE (1) PE20081558A1 (en)
PT (3) PT2109608E (en)
SI (2) SI2336120T1 (en)
TW (1) TWI528961B (en)
UA (1) UA97658C2 (en)
ZA (1) ZA200903898B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (en) * 2016-09-14 2017-03-15 陕西科技大学 A kind of synthetic method for preparing PARP inhibitor Niraparib
CN106432188A (en) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 Preparation method of anti-cancer drug 2-[4-((3S)-3-Piperidinyl) phenyl]-2H-Indazole-7-Formamide
CN106432187A (en) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 Chiral resolution method of 2-[4-(-3-piperidyl)phenyl]-2H-indazole-7-formamide
CN106632244A (en) * 2016-09-30 2017-05-10 陕西科技大学 A novel synthetic method for preparing an anticancer medicine Niraparib
CN106467513A (en) * 2016-09-30 2017-03-01 陕西科技大学 A kind of synthetic method preparing Niraparib
CN108201537A (en) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof
JP2020512347A (en) * 2017-03-27 2020-04-23 テサロ， インコーポレイテッド Niraparib formulation
CN109081828B (en) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 Poly (ADP-ribose) polymerase inhibitor, preparation method and application
MX2020003760A (en) 2017-09-26 2020-07-29 Tesaro Inc Niraparib formulations.
CN108084157A (en) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 A kind of synthetic method of Ni Lapani
CN108203404A (en) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani
CA3169303A1 (en) 2020-02-24 2021-09-02 Xiaokun SHEN Application of poly adp-ribose polymerase inhibitors in corona virus resistance
CN115611860B (en) * 2021-07-13 2024-06-11 上海博璞诺科技发展有限公司 Method for synthesizing nilaparib

Also Published As

Publication number Publication date
ZA200903898B (en) 2010-04-28
MY147789A (en) 2013-01-31
DK2109608T3 (en) 2011-07-11
GB0700432D0 (en) 2007-02-21
LT2805945T (en) 2019-06-25
PT2336120E (en) 2014-10-01
HN2009001260A (en) 2012-03-26
ES2728199T3 (en) 2019-10-22
CN101578279B (en) 2013-07-17
TW200836731A (en) 2008-09-16
CN101578279A (en) 2009-11-11
NZ578256A (en) 2011-12-22
ME03481B (en) 2020-01-20
UA97658C2 (en) 2012-03-12
PT2109608E (en) 2011-05-30
DE602008005711D1 (en) 2011-05-05
TWI528961B (en) 2016-04-11
ATE502933T1 (en) 2011-04-15
HUE044513T2 (en) 2019-10-28
ES2362214T3 (en) 2011-06-29
NI200900135A (en) 2010-08-30
CR10910A (en) 2010-01-19
SI2109608T1 (en) 2011-07-29
SI2336120T1 (en) 2014-10-30
ES2509115T3 (en) 2014-10-17
PE20081558A1 (en) 2008-10-30
LUC00072I2 (en) 2018-07-04
DK2336120T3 (en) 2014-10-06

Similar Documents

Publication Publication Date Title
MX2009007200A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors.
ZA200903898B (en) Amide substituted indazoles as poly (ADP-Ribose)polymerase (PARP) inhibitors
MX2010005070A (en) Pyridazinone derivatives as parp inhibitors.
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
MX2012002179A (en) Heterocyclic oxime compounds.
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
ATE543811T1 (en) PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS
EA201190158A1 (en) Derivatives of benzofuranyl for use as glucose kinase inhibitors
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
MX2012001838A (en) Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
WO2008017883A3 (en) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
EA201070864A1 (en) NEW HETEROCYCLIC COMPOUNDS
MX2012007582A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds.
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
PH12015500418A1 (en) Pyridine derivative and medicine
GB201114389D0 (en) Novel compounds
UA101367C2 (en) Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS